Printer Friendly
The Free Library
19,604,530 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Company Profile for Optimer Pharmaceuticals Inc.


Calendar Editors/Health/Medical Writers

--(BUSINESS WIRE)

Optimer Pharmaceuticals Inc. is an emerging biopharmaceutical company with a specialty expertise in anti-infectives and a powerful drug discovery and development engine based on novel chemistry technologies. The company was registered as a Delaware Corporation A Delaware corporation is a corporation chartered in the U.S. state of Delaware. Delaware is well known as a corporate haven, and thus, over 50% of US publicly-traded corporations and 58% of the Fortune 500 companies are incorporated in the state.  in 1999 and has licensed novel carbohydrate chemistries and technologies from The Scripps Research Institute ("TSRI TSRI The Scripps Research Institute
TSRI Taiwan Sugar Research Institute
") and The Memorial Sloan-Kettering Cancer Center The Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City is a cancer treatment and research institution founded in 1884 as the New York Cancer Hospital. The main campus is located at 1275 York Avenue, between 67th and 68th Streets, with other locations in New  ("MSKCC MSKCC Memorial Sloan-Kettering Cancer Center "). By combining world-class scientific and management talent with cutting edge technology, the company has created an efficient drug development engine unequaled in the field of anti-infective drug discovery.

Carbohydrates are fundamental to many biological processes and play a major role in diseases such as infection, cancer and immune-related disorders. And yet, due to difficulties and complexities associated with carbohydrate drug synthesis, carbohydrates are the least explored of all biomolecules This page aims to list articles on Wikipedia that describe particular biomolecules or types of biomolecules.

This list is not necessarily complete or up to date - if you see an article that should be here but isn't (or one that shouldn't be here but is), please update the page
 in the drug discovery arena. The company's discovery platform consists of two key technologies: (1) OPopS(R)(Optimer Programmable One Pot Synthesis), is a rational methodology that enables the rapid, low cost synthesis of a wide array of carbohydrate molecules, and (2) De Novo [Latin, Anew.] A second time; afresh. A trial or a hearing that is ordered by an appellate court that has reviewed the record of a hearing in a lower court and sent the matter back to the original court for a new trial, as if it had not been previously heard nor decided.  Glycosylation Technology enables the facile (language) Facile - A concurrent extension of ML from ECRC.

http://ecrc.de/facile/facile_home.html.

["Facile: A Symmetric Integration of Concurrent and Functional Programming", A. Giacalone et al, Intl J Parallel Prog 18(2):121-160, Apr 1989].
 modification of existing pharmacophores for drug optimization.

Optimer Pharmaceuticals Inc. U.S. has headquarters in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. . The company's 18,360 square foot facility houses the company's administration, biology and chemistry research laboratories. The company has two subsidiaries located in Sinagapore and Taiwan.

   Company:                Optimer Pharmaceuticals, Inc.

   Headquarters Address:   10110 Sorrento Valley Road
                           Suite C
                           San Diego, CA 92121

   Main Telephone:         858-909-0736

   Website:                www.optimerpharma.com

   Type of Organization:   Private

   Industry:               Health: Pharmaceutical

   Key Executives:         President: Michael Chang
                           Vice President Finance:
                           David Duncan
                           Vice President Corporate Affairs:
                           Tessie Che

   Public Relations
     Contact:              Christina Donaghy
     Phone:                858-909-0736
     Email:                cdonaghy@optimerpharma.com
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Apr 16, 2004
Words:283
Previous Article:Company Profile for HotSkills, Inc.
Next Article:Company Profile for KC,I. - Kasdan Communications, Inc.



Related Articles
VALIGEN ACQUIRES BERLIN-BASED INFOGEN AND PHENOTYPE DATABASE.
Optimer Pharmaceuticals Licenses Fluoroquinolone Antibiotic From Nippon Shinyaku.
Optimer Pharmaceuticals Receives US$1.9 Million in SBIR Awards.
Optimer Pharmaceuticals Secures $34.2 Million Financing in 2005.
Optimer Pharmaceuticals Initiates Phase 3 Clinical Trials of OPT-99 for the Treatment of Gastroenteritis.
Optimer Pharmaceuticals Names John D. Prunty Chief Financial Officer.
Optimer Pharmaceuticals Announces Fourth Quarter and Full Year 2006 Financial Results.
Optimer Pharmaceuticals Initiates Second Phase 3 Trial of OPT-80 for CDAD.
Optimer Pharmaceuticals to Present at Two Upcoming Investor Conferences.
Optimer Pharmaceuticals Reports First Quarter 2007 Financial Results Including Payment of $20 Million to Par Pharmaceutical to Reacquire the North...

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles